RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update
Analyst conference call
The Company will hold an analyst conference call at
Conference Call Details
US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551
US/Canada Participant International Dial-In Number: (914) 987-7290
United Kingdom Participant Dial-In Number: 080 0028 8438
Conference ID: 7673467
Webcast Registration link:
RenalytixAI will be hosting a live online presentation open to all investors at
The presentation will be hosted through the digital platform
For those investors who have already registered and added to meet the Company, they will automatically be invited.
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/renalytixai-to-announce-financial-results-for-full-year-ended-june-30-2020-and-provide-corporate-update-301153816.html
Renalytix AI plc, www.renalytixai.com, James McCullough, CEO Via Walbrook PR. Stifel (Nominated Adviser, Joint Broker) Alex Price / Nicholas Moore, Tel: 020 7710 7600. N+1 Singer (Joint Broker), Aubrey Powell / George Tzimas (Corporate Finance), Tom Salvesen (Corporate Broking) Tel: 020 7496 3000. Walbrook PR Limited, Tel: 020 7933 8780 or email@example.com, Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303. US Investor Contact: Gilmartin Group firstname.lastname@example.org, Carrie Mendivil / Kelly Gura + 1 (415)-937-5405.